Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder
Psychotherapy and Psychosomatics, Volume 88, No. 5, Year 2019
Notification
URL copied to clipboard!
Description
Major depressive disorder (MDD) is a complex mental illness with unmet therapeutic needs. The antidepressant effects of ω-3 polyunsaturated fatty acids (n-3 PUFAs) have been widely reported. The subcommittee of the International Society for Nutritional Psychiatry Research organized an expert panel and conducted a literature review and a Delphi process to develop a consensus-based practice guideline for clinical use of n-3 PUFAs in MDD. The guideline focuses on 5 thematic areas: General concepts, acute treatment strategy, depression recurrence monitoring and prevention, use in special populations, and potential safety issues. The key practice guidelines contend that: (1) clinicians and other practitioners are advised to conduct a clinical interview to validate clinical diagnoses, physical conditions, and measurement-based psychopathological assessments in the therapeutic settings when recommending n-3 PUFAs in depression treatment; (2) with respect to formulation and dosage, both pure eicosapentaenoic acid (EPA) or an EPA/docosahexaenoic acid (DHA) combination of a ratio higher than 2 (EPA/DHA >2) are considered effective, and the recommended dosages should be 1-2 g of net EPA daily, from either pure EPA or an EPA/DHA (>2:1) formula; (3) the quality of n-3 PUFAs may affect therapeutic activity; and (4) potential adverse effects, such as gastrointestinal and dermatological conditions, should be monitored, as well as obtaining comprehensive metabolic panels. The expert consensus panel has agreed on using n-3 PUFAs in MDD treatment for pregnant women, children, and the elderly, and prevention in high-risk populations. Personalizing the clinical application of n-3 PUFAs in subgroups of MDD with a low Omega-3 Index or high levels of inflammatory markers might be regarded as areas that deserve future research. © 2019 S. Karger AG, Basel. All rights reserved.
Authors & Co-Authors
Mischoulon, David
United States, Boston
Massachusetts General Hospital
Sarris, Jerome
Australia, Penrith
Western Sydney University
Australia, Melbourne
University of Melbourne
Hibbeln, Joseph R.
United States, Bethesda
National Institute on Alcohol Abuse and Alcoholism Niaaa
Hamazaki, Kei
Japan, Toyama
University of Toyama
Freeman, Marlene P.
United States, Boston
Massachusetts General Hospital
Maes, Michael H.J.
Thailand, Bangkok
Chulalongkorn University
Matsuoka, Yutaka J.
Japan, Tokyo
National Cancer Center Japan
Belmaker, Robert Haim
Israel, Beer-sheva
Ben-gurion University of the Negev
Jacka, Felice Nellie
Australia, Geelong
Deakin University
Pariante, Carmine M.
United Kingdom, London
King's College London
Berk, Michael
Australia, Melbourne
University of Melbourne
Marx, Wolfgang
Australia, Geelong
Deakin University
Su, Kuanpin
Taiwan, Taichung
China Medical University Hospital
Taiwan, Taichung
China Medical University
Statistics
Citations: 99
Authors: 13
Affiliations: 13
Identifiers
Doi:
10.1159/000502652
ISSN:
00333190
Research Areas
Maternal And Child Health
Mental Health
Noncommunicable Diseases
Study Approach
Systematic review
Participants Gender
Female